Compare Devon Energy Corp (DVN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Devon Energy Corp trades at $45.45 (market cap $49.90B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.7× Devon Energy Corp's market cap, and Devon Energy Corp pays a 2.82% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| DVN | VRTX | |
|---|---|---|
Market Cap | $49.90B | $132.79B |
Sector | Energy | Health |
52-Week High | $52.07 | $529.65 |
52-Week Low | $31.74 | $376.62 |
Enterprise Value | $60.63B | $126.92B |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $42.98, down 0.3% with a bearish technical signal. The company reported strong Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising its dividend 33% and accelerating debt reduction. Valuation metrics appear attractive with P/E of 9.34 and EV/EBITDA of 6.59, though net income margins have declined from 31.4% in 2022 to 15.4% in 2025.
The outlook remains positive with 71% analyst buy ratings and a $61.91 consensus price target representing 44% upside. Key catalysts include merger synergies from Coterra integration and strong free cash flow generation supporting shareholder returns. Risks include oil price volatility and execution of the $1B+ synergy target by 2027.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
